RIGEL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of -$82.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-03-03
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was -$82.00K, a 278.26% decline from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was $46.00K, a 39.39% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $33.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | -$82.00K 10-K · filed 2026-03-03 |
| 2024-12-31 | $46.00K 10-K · filed 2026-03-03 |
| 2023-12-31 | $33.00K 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |